Peptide carriers gain more and more interest for efficient drug delivery as an elegant targeted treatment in modern medicine. Their direct cellular administration avoids negative side effects which may occur during systemic drug application. Peptide carriers not only provide a broad variety of applications and combinatory options using nano- and microparticles but also open the door for individualized therapy concepts. For example, drug combinations using time-controlled release or specific targeted treatments are possible depending on the genetic basis of heterogeneous diseases (as in several cancer types) or diseases arising from chronic inflammations. This study—using cell penetrating peptides originating from human calcitonin and the active agent α-antitrypsin—can be regarded as a pilot study extendible to a broad range of drugs and active agents. The approach by Leßig and coworkers will allow the development of effective delivery systems for a wide range of potent therapeutic molecules with restricted availability and delivery capacity using conventional methods.
Read more about how Peptied Carriers can be Trojan Horses for Targeted Therapies in the following article featured in the May issue of Cytometry Part A:
Efficient inhibition of human leukocytic elastase by means of α1-antitrypsin/peptide complexes
Jacqueline Leßig, Uta Reibetanz, Maria Schönberg and Ines Neundorf
Article first published online: 25 MAR 2013 | DOI: 10.1002/cyto.a.22270
Link to article: http://onlinelibrary.wiley.com/doi/10.1002/cyto.a.22270/full